Clinical trial
A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy, Including Lenalidomide and a Proteasome Inhibitor
NCT03475628 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy, Including Lenalidomide and a Proteasome Inhibitor
- Lead sponsor
- Hellenic Society of Hematology
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 21, 2018
- Completion date
- February 20, 2020
- Enrollment
- 57 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.